Guardant Health Will Not Go With NeoGenomics Deal: Bloomberg

by Vandana Singh, Benzinga Editor

October 4, 2021 12:08 PM | 1 min read | Make a Comment

Guardant Health Inc GH has decided not to pursue a potential acquisition of NeoGenomics Inc NEO, Bloomberg reported citing people familiar with the matter.
Related: Guardant Health Weighing NeoGenomics Acquisition: Bloomberg.
Guardant had hoped to use a tie-up with NeoGenomics to boost its reach into community cancer facilities, typically smaller, local clinics.
Reasons for the abandoned talks couldn’t immediately be learned, the report mentioned.
Before the talks fell apart, SVB Leerink’s analyst Puneet Souda noted that though the combination would be favorable for Guardant and strengthen its pathology business, it would also dilute its growth and margins.
Price Action: GH stock is trading 2.74% higher at $110.23, and NEO stock is down 7.86% at $44.69 on the last check Monday.